Showing 1196 results
- Key Release /Ad hoc announcement pursuant to Art. 53 LR Ligelizumab, a high-affinity anti-IgE antibody, demonstrated superiority compared with placebo at Week 12 in Phase III PEARL 1 and…
- Media Release /Ociperlimab adds innovative and complementary late-stage TIGIT inhibitor to an Oncology portfolio poised for growth Two Phase III trials underway in non-small cell lung cancer and additional studies…
- Media Release /Biologics License Application (BLA) is supported by analytical, pre-clinical and clinical data, proposed biosimilar trastuzumab developed by EirGenix, Inc. Trastuzumab is monoclonal…
- Media Release /Submission is supported by comprehensive package of analytical, pre-clinical and clinical data, proposed biosimilar trastuzumab developed by EirGenix, Inc.Breast cancer is one of most common types of…
- Media Release /There are no currently approved therapies impacting disease progression for the up to 8 million people suffering from geographic atrophy (GA)1,2 Acquisition will add GT005 to the Novartis portfolio…
- Key Release /Ad hoc announcement pursuant to Art. 53 LR With two maintenance doses a year, Leqvio is the first and only FDA-approved small interfering RNA (siRNA) therapy for LDL-C (bad cholesterol…
- Media Release /New approvals are based on JUNIPERA trial data showing Cosentyx® (secukinumab) demonstrated reduced flare risk versus placebo and improvement in disease activity observed over two years across both…
- Media Release /Shareholders approve 27th consecutive dividend increase to CHF 3.30 (+3.1%) per share for 2023; representing a 3.7% yield1 and approximately 58% payout of free cash flowShareholders confirm Joerg…
- Media Release /Les actionnaires approuvent la 27e augmentation consécutive du dividende qui passe à CHF 3,30 (+3,1%) par action pour 2023 ; représentant un rendement de 3,7%1 et une distribution du…
- Key Release /
Novartis delivers double-digit sales growth and core margin expansion in Q1; FY 2024 guidance raised
Ad hoc announcement pursuant to Art. 53 LRQ1 net sales grew +11% (cc1, +10% USD) with core operating income up +22% (cc, +16% USD) Key growth drivers continued strong sales momentum including…
Pagination
- ‹ Previous page
- 1
- …
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- › Next page